Karolina Orywal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karolina Orywal has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Wojciech Jelski
Department of Biochemical Diagnostics, Medical University, Bialystok, Poland
28 shared publications Maciej Szmitkowski
Department of Biochemical Diagnostics, Medical University of Białystok, Poland
23 shared publications- Barbara Mroczko
Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
15 shared publications - Tadeusz Werel
Department of Urology, Medical University of Bialystok, Bialystok, Poland
7 shared publications - Monika Zajkowska
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
6 shared publications - Teresa Sierpinska
Department of Prosthetic Dentistry, Medical University of Bialystok, Sklodowska-Curie Str. 24a, 15-276 Bialystok, Poland
6 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9955
Psychobiotics and Trace Elements in Neurodegenerative Diseases: From Independent Modulators to Potential Interactions Within the Microbiota–Gut–Brain Axis—Narrative Review
The microbiota–gut–brain axis represents an important bidirectional communication network linking the gastrointestinal tract and the central nervous system and may contribute to processes involved in neurodegeneration. Increasing attention has been directed toward psychobiotics as potential modulators of the microbiota–gut–brain axis, while accumulating evidence also indicates that disturbed trace-element homeostasis may contribute to the pathogenesis of neurodegenerative diseases. This review summarizes current evidence on the roles of psychobiotics and trace elements and examines their potential interplay within the microbiota–gut–brain axis. The review discusses bidirectional interactions between the gut microbiota and trace elements, the potential effects of psychobiotic interventions on trace-element homeostasis, and the possible implications of these interactions for neurodegenerative processes. Taken together, current findings indicate that the gut microbiota, psychobiotics, and trace elements may constitute an interconnected system influencing intestinal and systemic homeostasis as well as biological processes relevant to nervous system function. However, direct evidence demonstrating the clinical relevance of interactions between these components remains limited. Moreover, available evidence is largely based on experimental studies, while clinical findings remain scarce and heterogeneous. Further characterization of this interplay may improve our understanding of mechanisms underlying neurodegeneration and provide a basis for the development of more targeted and personalized approaches to supporting neurological health.
- 6 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9955
Open AccessPsychobiotics and Trace Elements in Neurodegenerative Diseases: From Independent Modulators to Potential Interactions Within the Microbiota–Gut–Brain Axis—Narrative Review
The microbiota–gut–brain axis represents an important bidirectional communication network linking the gastrointestinal tract and the central nervous system and may contribute to processes involved in neurodegeneration. Increasing attention has been directed toward psychobiotics as potential modulators of the microbiota–gut–brain axis, while accumulating evidence also indicates that disturbed trace-element homeostasis may contribute to the pathogenesis of neurodegenerative diseases. This review summarizes current evidence on the roles of psychobiotics and trace elements and examines their potential interplay within the microbiota–gut–brain axis. The review discusses bidirectional interactions between the gut microbiota and trace elements, the potential effects of psychobiotic interventions on trace-element homeostasis, and the possible implications of these interactions for neurodegenerative processes. Taken together, current findings indicate that the gut microbiota, psychobiotics, and trace elements may constitute an interconnected system influencing intestinal and systemic homeostasis as well as biological processes relevant to nervous system function. However, direct evidence demonstrating the clinical relevance of interactions between these components remains limited. Moreover, available evidence is largely based on experimental studies, while clinical findings remain scarce and heterogeneous. Further characterization of this interplay may improve our understanding of mechanisms underlying neurodegeneration and provide a basis for the development of more targeted and personalized approaches to supporting neurological health.
- Open Access
- 11 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7042
Comparative Analysis of Alcohol and Aldehyde Dehydrogenase Activities in Prostate Cancer and Benign Prostatic Hyperplasia
Background: Prostate cancer (PCa) remains one of the most frequently diagnosed cancers in men worldwide, and there is growing interest in the role of metabolic reprogramming in its development. Key metabolic pathways include alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), which are enzymes involved in the oxidation of alcohols and aldehydes, the detoxification of xenobiotics, and the regulation of cell proliferation and the oxidative stress response. Despite well-documented changes in enzyme activity in other malignancies, their activity in prostate tissue has not yet been thoroughly investigated. This study aimed to evaluate the activity of total ADH and its isoenzymes (classes I–IV), and ALDH classes I and III, in prostate cancer tissue compared with benign prostatic hyperplasia (BPH). Methods: Enzyme activities were determined using spectrophotometric and fluorometric methods in prostate tissue obtained from 48 patients with PCa (26 with low-risk and 22 with intermediate-risk disease) and from 42 patients with benign prostatic hyperplasia (BPH). The study groups were compared using non-parametric statistical tests, with p < 0.05 considered statistically significant. Results: The isoenzyme ADH class III showed the highest activity in both studied groups. The activity of ADH class I was significantly higher in PCa tissue compared with BPH (p = 0.0499), while ALDH I and III activity was also significantly higher in PCa tissue than in BPH (p = 0.0007). No significant differences were observed in total ADH or its other isoenzymes. Significant correlations were found among some ADH isoenzymes, but not with ALDH. Conclusions: Increased activity of class I ADH and ALDH enzymes in prostate cancer tissue may reflect disease-related metabolic changes and suggest their potential significance in the biology of prostate cancer. These findings provide new insights into metabolic reprogramming in prostate cancer and support the need for further studies to determine the biological and potential clinical significance of these enzymes.
- 11 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7042
Open AccessComparative Analysis of Alcohol and Aldehyde Dehydrogenase Activities in Prostate Cancer and Benign Prostatic Hyperplasia
Background: Prostate cancer (PCa) remains one of the most frequently diagnosed cancers in men worldwide, and there is growing interest in the role of metabolic reprogramming in its development. Key metabolic pathways include alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), which are enzymes involved in the oxidation of alcohols and aldehydes, the detoxification of xenobiotics, and the regulation of cell proliferation and the oxidative stress response. Despite well-documented changes in enzyme activity in other malignancies, their activity in prostate tissue has not yet been thoroughly investigated. This study aimed to evaluate the activity of total ADH and its isoenzymes (classes I–IV), and ALDH classes I and III, in prostate cancer tissue compared with benign prostatic hyperplasia (BPH). Methods: Enzyme activities were determined using spectrophotometric and fluorometric methods in prostate tissue obtained from 48 patients with PCa (26 with low-risk and 22 with intermediate-risk disease) and from 42 patients with benign prostatic hyperplasia (BPH). The study groups were compared using non-parametric statistical tests, with p < 0.05 considered statistically significant. Results: The isoenzyme ADH class III showed the highest activity in both studied groups. The activity of ADH class I was significantly higher in PCa tissue compared with BPH (p = 0.0499), while ALDH I and III activity was also significantly higher in PCa tissue than in BPH (p = 0.0007). No significant differences were observed in total ADH or its other isoenzymes. Significant correlations were found among some ADH isoenzymes, but not with ALDH. Conclusions: Increased activity of class I ADH and ALDH enzymes in prostate cancer tissue may reflect disease-related metabolic changes and suggest their potential significance in the biology of prostate cancer. These findings provide new insights into metabolic reprogramming in prostate cancer and support the need for further studies to determine the biological and potential clinical significance of these enzymes.
- Open Access
- 11 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8077
Immunometabolic Biomarkers in Colorectal Cancer: An Exploratory Diagnostic Evaluation of PBEF/NAMPT, Chemerin, and Osteopontin
Immunometabolic dysregulation plays a pivotal role in colorectal cancer (CRC) development and progression. Among the molecules linking inflammation, metabolism, and tumorigenesis, pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase (PBEF/NAMPT), chemerin, and osteopontin (OPN) have emerged as promising circulating biomarkers. This single-center study evaluated their diagnostic performance in patients with colorectal cancer and compared their utility with established tumor markers. Serum concentrations of PBEF/NAMPT, chemerin, and OPN were determined using a magnetic bead-based multiplex immunoassay (Luminex technology), whereas carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were measured by chemiluminescent microparticle immunoassay (CMIA). The study included 76 patients with colorectal cancer and 38 healthy, colonoscopy-negative controls. Differences between groups were assessed using the Mann–Whitney U, Kruskal–Wallis and post hoc tests, and diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis. Serum concentrations of PBEF/NAMPT and OPN were significantly higher in patients with CRC than in healthy controls, whereas chemerin did not differ significantly between groups. Among the investigated immunometabolic biomarkers, OPN demonstrated the highest diagnostic accuracy (AUC = 0.747), followed by PBEF/NAMPT (AUC = 0.624), whereas chemerin showed no significant diagnostic value (AUC = 0.559). Combining immunometabolic biomarkers with CEA yielded numerically higher AUC values than CEA alone, with the OPN + CEA panel reaching the highest diagnostic accuracy (AUC = 0.910), followed by the PBEF/NAMPT + CEA combination (AUC = 0.875); however, these increases did not reach statistical significance when formally compared with CEA alone. Among the evaluated immunometabolic biomarkers, OPN demonstrated the greatest diagnostic potential for colorectal cancer, and its combination with CEA warrants further investigation, although these findings should be considered exploratory given the limited sample size and the absence of external validation. Larger, multicenter studies using clinically relevant comparator groups are needed to establish the clinical utility of such multimarker strategies for the non-invasive diagnosis of CRC.
- 11 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8077
Open AccessImmunometabolic Biomarkers in Colorectal Cancer: An Exploratory Diagnostic Evaluation of PBEF/NAMPT, Chemerin, and Osteopontin
Immunometabolic dysregulation plays a pivotal role in colorectal cancer (CRC) development and progression. Among the molecules linking inflammation, metabolism, and tumorigenesis, pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase (PBEF/NAMPT), chemerin, and osteopontin (OPN) have emerged as promising circulating biomarkers. This single-center study evaluated their diagnostic performance in patients with colorectal cancer and compared their utility with established tumor markers. Serum concentrations of PBEF/NAMPT, chemerin, and OPN were determined using a magnetic bead-based multiplex immunoassay (Luminex technology), whereas carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were measured by chemiluminescent microparticle immunoassay (CMIA). The study included 76 patients with colorectal cancer and 38 healthy, colonoscopy-negative controls. Differences between groups were assessed using the Mann–Whitney U, Kruskal–Wallis and post hoc tests, and diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis. Serum concentrations of PBEF/NAMPT and OPN were significantly higher in patients with CRC than in healthy controls, whereas chemerin did not differ significantly between groups. Among the investigated immunometabolic biomarkers, OPN demonstrated the highest diagnostic accuracy (AUC = 0.747), followed by PBEF/NAMPT (AUC = 0.624), whereas chemerin showed no significant diagnostic value (AUC = 0.559). Combining immunometabolic biomarkers with CEA yielded numerically higher AUC values than CEA alone, with the OPN + CEA panel reaching the highest diagnostic accuracy (AUC = 0.910), followed by the PBEF/NAMPT + CEA combination (AUC = 0.875); however, these increases did not reach statistical significance when formally compared with CEA alone. Among the evaluated immunometabolic biomarkers, OPN demonstrated the greatest diagnostic potential for colorectal cancer, and its combination with CEA warrants further investigation, although these findings should be considered exploratory given the limited sample size and the absence of external validation. Larger, multicenter studies using clinically relevant comparator groups are needed to establish the clinical utility of such multimarker strategies for the non-invasive diagnosis of CRC.
- Open Access
- 11 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6197
Serum CCL2 and CCL7 in Prostate Cancer: Evaluation of Their Diagnostic Utility in Comparison with Benign Prostatic Hyperplasia and Healthy Controls
Prostate cancer (PCa) is the most common malignancy in men. Recent evidence indicates a correlation between modulation of the tumor microenvironment, tumor growth and metastasis. Chemokines, including C-C chemokine ligand 2 (CCL2) and C-C chemokine ligand 7 (CCL7), participate in regulating inflammation, angiogenesis, and the recruitment of immunosuppressive cells. This study aimed to assess the diagnostic potential of serum CCL2 and CCL7 in patients with PCa, benign prostatic hyperplasia (BPH) and healthy controls. The study included 53 patients with PCa, divided into groups at low, intermediate, and high risk of disease progression, 55 with BPH, and 30 healthy controls. CCL2 and CCL7 concentrations were measured using a multiplex Luminex assay. Serum CCL7 concentration in PCa patients was significantly lower compared to controls. No significant differences in its concentration were found between PCa and BPH patients or between PCa subgroups at different risk levels. CCL7 demonstrated promising sensitivity (96.2%) and AUC (0.917). However, its ability to distinguish PCa from BPH was limited. CCL2 concentrations were significantly lower in the PCa group only compared to the BPH group. These results suggest that CCL7 may represent a potential adjunct marker within multimarker diagnostic strategies for prostate cancer, while CCL2 showed limited diagnostic utility.
- 11 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6197
Open AccessSerum CCL2 and CCL7 in Prostate Cancer: Evaluation of Their Diagnostic Utility in Comparison with Benign Prostatic Hyperplasia and Healthy Controls
Prostate cancer (PCa) is the most common malignancy in men. Recent evidence indicates a correlation between modulation of the tumor microenvironment, tumor growth and metastasis. Chemokines, including C-C chemokine ligand 2 (CCL2) and C-C chemokine ligand 7 (CCL7), participate in regulating inflammation, angiogenesis, and the recruitment of immunosuppressive cells. This study aimed to assess the diagnostic potential of serum CCL2 and CCL7 in patients with PCa, benign prostatic hyperplasia (BPH) and healthy controls. The study included 53 patients with PCa, divided into groups at low, intermediate, and high risk of disease progression, 55 with BPH, and 30 healthy controls. CCL2 and CCL7 concentrations were measured using a multiplex Luminex assay. Serum CCL7 concentration in PCa patients was significantly lower compared to controls. No significant differences in its concentration were found between PCa and BPH patients or between PCa subgroups at different risk levels. CCL7 demonstrated promising sensitivity (96.2%) and AUC (0.917). However, its ability to distinguish PCa from BPH was limited. CCL2 concentrations were significantly lower in the PCa group only compared to the BPH group. These results suggest that CCL7 may represent a potential adjunct marker within multimarker diagnostic strategies for prostate cancer, while CCL2 showed limited diagnostic utility.
- Open Access
- 2 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3218
Matrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review
Bladder cancer (BC) is one of the most commonly diagnosed cancers of the genitourinary system and ranks ninth in terms of incidence worldwide. Due to the varied clinical course of the disease and the frequent tendency for tumor recurrence, diagnostic studies are being conducted to find non-invasive and prognostic markers that could be helpful in diagnosing BC. The aim of this review was to present the current state of knowledge on the role of extracellular matrix metalloproteinases (MMPs) and pro-inflammatory cytokines in the pathogenesis of bladder cancer, as well as to assess their potential as biomarkers measured in body fluids. The study reviewed the literature published in English between 2012 and 2025. The studies included clinical and experimental research analysing the expression and activity of selected metalloproteinases, including MMP-2, MMP-9, MMP-7 and MMP-1, and pro-inflammatory cytokines such as interleukins (ILs): IL-6, IL-8, IL-17, and IFN-γ in serum, urine, and tumor tissues of patients with BC, using immunochemical methods and genetic analyses. The collected data indicate that MMPs play a key role in the degradation of the extracellular matrix, facilitating invasion, angiogenesis, and metastasis. Elevated concentrations of MMP-2 and MMP-9, especially in urine, correlate with the clinical stage and histopathological malignancy of the tumor. MMP-7 may be important in the early stages of carcinogenesis, while MMP-1 shows promising potential in multi-marker panels. At the same time, chronic inflammation and increased pro-inflammatory cytokine activity play a key role in modulating the tumor microenvironment. IL-6 and IL-8 have high diagnostic value in urine tests, with IL-6 also serving as a prognostic marker. IL-17 is associated with more aggressive forms of the disease, while IFN-γ may reflect the immune response to BC treatment. There is also evidence of positive feedback between cytokines and MMPs, which intensifies the process of tumor invasion and progression. Therefore, both extracellular matrix metalloproteinases and pro-inflammatory cytokines may be promising non-invasive biomarkers of bladder cancer. Their combined assessment can increase the diagnostic and prognostic value compared to the analysis of individual parameters. However, further multicentre prospective studies are needed for clinical validation and standardisation of the methods of determination.
- 2 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3218
Open AccessMatrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review
Bladder cancer (BC) is one of the most commonly diagnosed cancers of the genitourinary system and ranks ninth in terms of incidence worldwide. Due to the varied clinical course of the disease and the frequent tendency for tumor recurrence, diagnostic studies are being conducted to find non-invasive and prognostic markers that could be helpful in diagnosing BC. The aim of this review was to present the current state of knowledge on the role of extracellular matrix metalloproteinases (MMPs) and pro-inflammatory cytokines in the pathogenesis of bladder cancer, as well as to assess their potential as biomarkers measured in body fluids. The study reviewed the literature published in English between 2012 and 2025. The studies included clinical and experimental research analysing the expression and activity of selected metalloproteinases, including MMP-2, MMP-9, MMP-7 and MMP-1, and pro-inflammatory cytokines such as interleukins (ILs): IL-6, IL-8, IL-17, and IFN-γ in serum, urine, and tumor tissues of patients with BC, using immunochemical methods and genetic analyses. The collected data indicate that MMPs play a key role in the degradation of the extracellular matrix, facilitating invasion, angiogenesis, and metastasis. Elevated concentrations of MMP-2 and MMP-9, especially in urine, correlate with the clinical stage and histopathological malignancy of the tumor. MMP-7 may be important in the early stages of carcinogenesis, while MMP-1 shows promising potential in multi-marker panels. At the same time, chronic inflammation and increased pro-inflammatory cytokine activity play a key role in modulating the tumor microenvironment. IL-6 and IL-8 have high diagnostic value in urine tests, with IL-6 also serving as a prognostic marker. IL-17 is associated with more aggressive forms of the disease, while IFN-γ may reflect the immune response to BC treatment. There is also evidence of positive feedback between cytokines and MMPs, which intensifies the process of tumor invasion and progression. Therefore, both extracellular matrix metalloproteinases and pro-inflammatory cytokines may be promising non-invasive biomarkers of bladder cancer. Their combined assessment can increase the diagnostic and prognostic value compared to the analysis of individual parameters. However, further multicentre prospective studies are needed for clinical validation and standardisation of the methods of determination.
- Open Access
- 8 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2490
Serum Chemokines CCL3 and CCL7 as Complementary Diagnostic Biomarkers Across Tumor Grades in Clear Cell Renal Cell Carcinoma
The long asymptomatic period of clear cell renal cell carcinoma, which leads to delayed diagnosis and poorer prognosis, poses a global challenge. Chemokines play a pivotal role in immune regulation and tumor progression, making them promising biomarker candidates. This study aimed to evaluate the usefulness of the C-C motif chemokine ligand 3 (CCL3) and C-C motif chemokine ligand 7 (CCL7) by assessing their serum concentrations in 40 patients with stage G1 + G2 and stage G3 + G4 renal cancer, as well as in 58 healthy volunteers. Chemokine concentrations were measured using a multiplex Luminex assay and analyzed statistically, including receiver operating characteristic (ROC) analysis. Serum CCL3 concentrations were significantly elevated in ccRCC patients compared to controls and increased with tumor grade, with the highest levels observed in patients with advanced disease (G3+G4). In contrast, serum CCL7 levels were significantly lower in ccRCC patients than in healthy individuals, with no significant differences between tumor grade subgroups. ROC analysis revealed comparable diagnostic performance of CCL3 and CCL7, with CCL3 showing a slightly higher area under the curve. CCL3 showed high sensitivity, whereas CCL7 exhibited higher specificity than sensitivity, and a relatively high positive predictive value, consistent with its inverse regulation in ccRCC. These findings suggest that serum CCL3 and CCL7 are oppositely regulated in ccRCC and may serve as complementary non-invasive biomarkers for renal cancer detection.
- 8 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2490
Open AccessSerum Chemokines CCL3 and CCL7 as Complementary Diagnostic Biomarkers Across Tumor Grades in Clear Cell Renal Cell Carcinoma
The long asymptomatic period of clear cell renal cell carcinoma, which leads to delayed diagnosis and poorer prognosis, poses a global challenge. Chemokines play a pivotal role in immune regulation and tumor progression, making them promising biomarker candidates. This study aimed to evaluate the usefulness of the C-C motif chemokine ligand 3 (CCL3) and C-C motif chemokine ligand 7 (CCL7) by assessing their serum concentrations in 40 patients with stage G1 + G2 and stage G3 + G4 renal cancer, as well as in 58 healthy volunteers. Chemokine concentrations were measured using a multiplex Luminex assay and analyzed statistically, including receiver operating characteristic (ROC) analysis. Serum CCL3 concentrations were significantly elevated in ccRCC patients compared to controls and increased with tumor grade, with the highest levels observed in patients with advanced disease (G3+G4). In contrast, serum CCL7 levels were significantly lower in ccRCC patients than in healthy individuals, with no significant differences between tumor grade subgroups. ROC analysis revealed comparable diagnostic performance of CCL3 and CCL7, with CCL3 showing a slightly higher area under the curve. CCL3 showed high sensitivity, whereas CCL7 exhibited higher specificity than sensitivity, and a relatively high positive predictive value, consistent with its inverse regulation in ccRCC. These findings suggest that serum CCL3 and CCL7 are oppositely regulated in ccRCC and may serve as complementary non-invasive biomarkers for renal cancer detection.
- Open Access
- 19 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1996
Cytokines and Chemokines as Emerging Biomarkers and Therapeutic Targets in Colorectal Cancer—Narrative Review
Colorectal cancer (CRC) is a significant global health challenge, characterized by an increasing incidence rate and high mortality rate. Early detection and effective treatment are crucial to improving patients’ quality of life. Cytokines and chemokines are key modulators of the tumor microenvironment, influencing the recruitment of immune cells, angiogenesis, proliferation, and metastasis. This narrative review summarizes the current knowledge regarding the potential diagnostic and therapeutic applications of selected cytokines and chemokines in CRC. We discuss their potential as biomarkers for early detection, prognosis, and prediction of treatment response. We also highlight emerging therapeutic strategies targeting cytokine and chemokine pathways, including immune checkpoint inhibitors, modulation of chemokine signaling, and the direct use of cytokines to enhance antitumor immunity, with particular emphasis on interleukin-6 (IL-6), C-X-C motif chemokine ligand 8 (CXCL8), C-C motif chemokine ligand 2 (CCL2), and the C-X-C motif chemokine ligand 12 (CXCL12)–C-X-C chemokine receptor type 4 (CXCR4) axis, which show consistent associations with tumor stage, metastasis, and treatment response. Integrating cytokine- and chemokine-based approaches with combination therapies could lead to more effective conventional treatments. In summary, this review emphasizes the potential of cytokines and chemokines as diagnostic tools and therapeutic targets, paving the way for more personalized and effective treatment strategies for colorectal cancer.
- 19 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1996
Open AccessCytokines and Chemokines as Emerging Biomarkers and Therapeutic Targets in Colorectal Cancer—Narrative Review
Colorectal cancer (CRC) is a significant global health challenge, characterized by an increasing incidence rate and high mortality rate. Early detection and effective treatment are crucial to improving patients’ quality of life. Cytokines and chemokines are key modulators of the tumor microenvironment, influencing the recruitment of immune cells, angiogenesis, proliferation, and metastasis. This narrative review summarizes the current knowledge regarding the potential diagnostic and therapeutic applications of selected cytokines and chemokines in CRC. We discuss their potential as biomarkers for early detection, prognosis, and prediction of treatment response. We also highlight emerging therapeutic strategies targeting cytokine and chemokine pathways, including immune checkpoint inhibitors, modulation of chemokine signaling, and the direct use of cytokines to enhance antitumor immunity, with particular emphasis on interleukin-6 (IL-6), C-X-C motif chemokine ligand 8 (CXCL8), C-C motif chemokine ligand 2 (CCL2), and the C-X-C motif chemokine ligand 12 (CXCL12)–C-X-C chemokine receptor type 4 (CXCR4) axis, which show consistent associations with tumor stage, metastasis, and treatment response. Integrating cytokine- and chemokine-based approaches with combination therapies could lead to more effective conventional treatments. In summary, this review emphasizes the potential of cytokines and chemokines as diagnostic tools and therapeutic targets, paving the way for more personalized and effective treatment strategies for colorectal cancer.
- Open Access
Analysis of Visfatin Concentration and Other Potential Biomarkers Associated with MASLD Development in Saliva and Serum of Patients with Obesity—A Pilot Study
Background/Objectives: Adipokines and cytokines, secreted by adipocytes and immune cells, play key roles in metabolic and inflammatory processes. This study aimed to assess the association between salivary visfatin levels and metabolic dysfunction-associated steatotic liver disease (MASLD), determine a salivary visfatin cutoff associated with increased risk of this disease, and examine correlations among selected adipokines, cytokines, and gelatinases in serum and saliva of obese patients. Methods: The study included 65 participants (40 women and 25 men) with a body mass index (BMI) ranging from 30.0 to 39.9 kg/m2, who were divided into groups based on whether the salivary visfatin concentration exceeded the quantification limit (1.229 ng/mL). Body composition analysis was performed using the bioelectrical impedance method, quantitative assessment of hepatic steatosis was carried out using transient elastography, and the concentrations of selected adipokines, cytokines, and gelatinases were determined in serum and saliva. Results: A relationship was observed between lower BMI and salivary visfatin concentrations below the quantification limit (p = 0.017), and between the absence of MASLD and visfatin levels below the quantification threshold in saliva (p = 0.05). Higher concentrations of interleukin-1β (p = 0.003) and matrix metalloproteinase-2 (p = 0.019) in saliva, as well as interleukin-6 (p = 0.002) in serum, were observed in the group with salivary visfatin levels above the quantification limit. Correlations were found between salivary and serum IL-6 concentrations (r = 0.30; p = 0.016) and between serum resistin and salivary IL-6 levels (r = 0.24; p = 0.056), as well as between serum IL-6 and salivary MMP-2 concentrations (r = 0.24; p = 0.059). Conclusions: In this pilot study, salivary visfatin levels were found to differ between obese individuals with and without MASLD and to be associated with selected anthropometric parameters and inflammatory markers, but the observed associations are exploratory and require confirmation.
Open AccessAnalysis of Visfatin Concentration and Other Potential Biomarkers Associated with MASLD Development in Saliva and Serum of Patients with Obesity—A Pilot Study
Background/Objectives: Adipokines and cytokines, secreted by adipocytes and immune cells, play key roles in metabolic and inflammatory processes. This study aimed to assess the association between salivary visfatin levels and metabolic dysfunction-associated steatotic liver disease (MASLD), determine a salivary visfatin cutoff associated with increased risk of this disease, and examine correlations among selected adipokines, cytokines, and gelatinases in serum and saliva of obese patients. Methods: The study included 65 participants (40 women and 25 men) with a body mass index (BMI) ranging from 30.0 to 39.9 kg/m2, who were divided into groups based on whether the salivary visfatin concentration exceeded the quantification limit (1.229 ng/mL). Body composition analysis was performed using the bioelectrical impedance method, quantitative assessment of hepatic steatosis was carried out using transient elastography, and the concentrations of selected adipokines, cytokines, and gelatinases were determined in serum and saliva. Results: A relationship was observed between lower BMI and salivary visfatin concentrations below the quantification limit (p = 0.017), and between the absence of MASLD and visfatin levels below the quantification threshold in saliva (p = 0.05). Higher concentrations of interleukin-1β (p = 0.003) and matrix metalloproteinase-2 (p = 0.019) in saliva, as well as interleukin-6 (p = 0.002) in serum, were observed in the group with salivary visfatin levels above the quantification limit. Correlations were found between salivary and serum IL-6 concentrations (r = 0.30; p = 0.016) and between serum resistin and salivary IL-6 levels (r = 0.24; p = 0.056), as well as between serum IL-6 and salivary MMP-2 concentrations (r = 0.24; p = 0.059). Conclusions: In this pilot study, salivary visfatin levels were found to differ between obese individuals with and without MASLD and to be associated with selected anthropometric parameters and inflammatory markers, but the observed associations are exploratory and require confirmation.
- Open Access
- 10 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (12) , 1480
The Protective Effect of Zinc Supplementation Against Oxidative Stress and Oxidative Modifications of Cellular Macromolecules in the Mandibular Bone of Rats Exposed to Cadmium
In a rat model simulating moderate and relatively high human exposure to cadmium (Cd; 5 and 50 mg/L, respectively, for 12 months), it was examined whether zinc (Zn) supplementation (30 and 60 mg/L, increasing the daily intake of this element by 71% and 146%, respectively) could protect against this xenobiotic-caused disruption of the oxidative–reductive balance in the mandibular bone tissue and the subsequent oxidative damage to nucleic acids, proteins, and lipids. The exposure to Cd weakened the enzymatic antioxidative barrier (superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)) and decreased the total antioxidative status (TAS) of this tissue. The treatment with Cd also increased the concentration of hydrogen peroxide (H2O2) and the total oxidative status (TOS) of the mandibular bone tissue, leading to the development of oxidative stress, as indicated by an elevated value of the oxidative stress index (OSI), and oxidative damage to nucleic acids, lipids, and proteins. Zn supplementation at 30 and 60 mg/L during Cd exposure at 5 and 50 mg/L effectively protected against the accumulation of this toxic heavy metal in mandibular bone tissue and prevented oxidative stress and oxidative modifications of nucleic acids, proteins, and lipids. In conclusion, increasing Zn intake by at least 71% during chronic oral exposure to Cd may prevent oxidative–antioxidative imbalance and the development of oxidative stress, thereby safeguarding cellular macromolecules in the mandibular bone tissue from oxidative damage. These findings highlight the potential role of Cd exposure in the aetiology of mandibular bone damage and provide the first evidence that Zn supplementation may represent an effective intervention to alleviate adverse impact of long-term oral exposure to Cd on mandibular bone.
- 10 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (12) , 1480
Open AccessThe Protective Effect of Zinc Supplementation Against Oxidative Stress and Oxidative Modifications of Cellular Macromolecules in the Mandibular Bone of Rats Exposed to Cadmium
In a rat model simulating moderate and relatively high human exposure to cadmium (Cd; 5 and 50 mg/L, respectively, for 12 months), it was examined whether zinc (Zn) supplementation (30 and 60 mg/L, increasing the daily intake of this element by 71% and 146%, respectively) could protect against this xenobiotic-caused disruption of the oxidative–reductive balance in the mandibular bone tissue and the subsequent oxidative damage to nucleic acids, proteins, and lipids. The exposure to Cd weakened the enzymatic antioxidative barrier (superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)) and decreased the total antioxidative status (TAS) of this tissue. The treatment with Cd also increased the concentration of hydrogen peroxide (H2O2) and the total oxidative status (TOS) of the mandibular bone tissue, leading to the development of oxidative stress, as indicated by an elevated value of the oxidative stress index (OSI), and oxidative damage to nucleic acids, lipids, and proteins. Zn supplementation at 30 and 60 mg/L during Cd exposure at 5 and 50 mg/L effectively protected against the accumulation of this toxic heavy metal in mandibular bone tissue and prevented oxidative stress and oxidative modifications of nucleic acids, proteins, and lipids. In conclusion, increasing Zn intake by at least 71% during chronic oral exposure to Cd may prevent oxidative–antioxidative imbalance and the development of oxidative stress, thereby safeguarding cellular macromolecules in the mandibular bone tissue from oxidative damage. These findings highlight the potential role of Cd exposure in the aetiology of mandibular bone damage and provide the first evidence that Zn supplementation may represent an effective intervention to alleviate adverse impact of long-term oral exposure to Cd on mandibular bone.
- Open Access
The Clinical Relevance of Tumor Biomarkers in Prostate Cancer—A Review
Prostate cancer is one of the most common malignancies in men worldwide. Therefore, there is an urgent need to develop accurate, accessible biomarkers for diagnosis, prognosis, and therapy monitoring. Tumor markers, which can be measured in blood, urine, or tissue, provide valuable information regarding tumor presence, progression, and response to treatment. This review provides a comprehensive overview of routinely used diagnostic and emerging biomarkers for prostate cancer, based on a systematic MEDLINE/PubMed search. Key biomarkers analyzed include PSA and its derivatives, PCA3, and TMPRSS2-ERG, as well as genomic tests such as Prolaris, Decipher, and ConfirmMDx, and liquid biopsy-based tests such as ExoDx Prostate and SelectMDx. This narrative review demonstrates that although PSA remains the mainstay of prostate cancer diagnosis, emerging molecular and genomic biomarkers are enhancing diagnostic specificity, refining risk stratification, and enabling more personalized patient care. The integration of routinely used and novel biomarkers can improve early detection, optimize treatment decisions, and ultimately improve outcomes of prostate cancer patients.
Open AccessThe Clinical Relevance of Tumor Biomarkers in Prostate Cancer—A Review
Prostate cancer is one of the most common malignancies in men worldwide. Therefore, there is an urgent need to develop accurate, accessible biomarkers for diagnosis, prognosis, and therapy monitoring. Tumor markers, which can be measured in blood, urine, or tissue, provide valuable information regarding tumor presence, progression, and response to treatment. This review provides a comprehensive overview of routinely used diagnostic and emerging biomarkers for prostate cancer, based on a systematic MEDLINE/PubMed search. Key biomarkers analyzed include PSA and its derivatives, PCA3, and TMPRSS2-ERG, as well as genomic tests such as Prolaris, Decipher, and ConfirmMDx, and liquid biopsy-based tests such as ExoDx Prostate and SelectMDx. This narrative review demonstrates that although PSA remains the mainstay of prostate cancer diagnosis, emerging molecular and genomic biomarkers are enhancing diagnostic specificity, refining risk stratification, and enabling more personalized patient care. The integration of routinely used and novel biomarkers can improve early detection, optimize treatment decisions, and ultimately improve outcomes of prostate cancer patients.